유방암에 대한 술전항암화학요법(Neoadjuvant Chemotherapy)의 반응도에 따른 잔여종양조직의 병리학적 특성

김종완; 정성구; 엄태익; 구본용; 강희준; 김이수

추천

검색

질문

자료유형: 학술저널

저자정보: 김종완 (한림대학교) 정성구 (한림대학교) 엄태익 (한림대학교) 구본용 (한림대학교) 강희준 (한림대학교) 김이수 (한림대학교)

저널정보: 대한외과학회 Annals of Surgical Treatment and Research 대한외과학회지 Vol.75 No.1

발행연도: 2008.7

수록면: 1 - 8 (8page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

이 논문의 연구 히스토리 (2)

2008

유방암에 대한 술전항암화학요법(Neoadjuvant Chemotherapy)의 반응도에 따른 잔여종양조직의 병리학적 특성

김종완 , 정성구 , 엄태익 외 3명 Annals of Surgical Treatment and Research 2008.07 학술저널

2006

유방암 환자에 있어 술전 항암 화학요법(Neoadjuvant Chemotherapy)의 효과와 그 예측 인자

김종완 , 이미열 , 엄태익 외 3명 대한외과학회 학술대회 초록집 2006.05 학술대회자료

이 논문의 후속연구가 궁금하신가요?
연관 학술논문 또는 학술발표를 통해 보다 발전된 연구결과를 확인하실 수 있습니다.
이 논문의 연구 히스토리 확인하기

초록· 키워드

오류제보하기

Purpose: There are questions about selecting the best postoperative chemotherapeutic regimen for breast cancer patients who have different response rates after neoadjuvant chemotherapy. The aim of this study was to examine the pathologic findings of residual tumors according to the response rate after neoadjuvant chemotherapy for breast cancer.
Methods: We obtained specimens of residual tumors from 43 breast cancer patients who received neoadjuvant chemotherapy followed by curative operation at the Department of Breast and Endocrine Surgery, Sacred Heart Hospital, between Oct. 2002 and Oct. 2006. Four patients received 3 cycles of FAC (5-FU, Adriamycin, Cyclophosphamide) and 39 patients received 3 cycles of AT (Adriamycin, Docetaxel). We analyzed the pathologic characteristics according to the response rate.
Results: The clinical response rate for neoadjuvant chemotherapy was 69.8%. There was no significant difference in the response rate for neoadjuvant chemotherapy between the AT and the FAC regimen groups. The tumors of the complete response group showed to be more ER-negative, PR-positive, p53-negative and c-erb-B2-positive and they had a lower Ki-67 staining index than the tumors of the partial response group. Moreover, the tumors of the clinical complete response group showed more triple (ER/PR/c-erb-B2) negative tumor than did the tumors of the partial response group.
Conclusion: Although the tumor responded to neoadjuvant chemotherapy, the pathologic findings of the residual tumors in the clinical complete response group differed from that of the partial response group. So, this should be considered for the selection of postoperative chemotherapeutic agents.

#Neoadjuvant chemotherapy #Response rate #Pathologic findings #술 전 항암화학요법 #반응률 #병리학적 특성

참고문헌 (30)

참고문헌 신청

1. [학술지(정기간행물)] - Park BW / 1994 / Induction chemotherapy in locally advanced breast cancer / J Korean Surg Soc 47 : 616 ~ 622

2. [학술지(정기간행물)] - Lee SH / 1990 / Preoperative chemotherapy in locally advanced breast cancer / J Korean Sur Soc 38 : 34 ~ 39

3. [학술지(정기간행물)] - Jacquillat CJ / 1990 / Results of neoadjuvant chemotherapy and radiaton in the breast-conserving treatment of 250 patients with all stages of infiltrative breast cancer / Cancer 66 : 119 ~ 129

4. [학술지(정기간행물)] - Rubens RD / 1980 / Combined chemotherapy and radiotherapy for locally advanced breast cancer / Eur J Cancer 16 : 351 ~ 356

5. [학술지(정기간행물)] - Lippman ME / 1986 / Treatment of locally advanced breast cancer using primary induction chemotherapy with hormonal synchronization followed by radiation therapy with or without debulking surgery / NCI Monogr 1 : 153 ~ 159

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!